Innovative Manufacturing Enzene Biosciences has developed and validated its patented fully-connected continuous manufacturing platform, EnzeneX, which enhances biologics production yields and reduces costs. This innovative technology presents opportunities for collaboration with companies seeking scalable, cost-effective biologics manufacturing solutions.

Global Expansion With recent facility expansion into New Jersey and plans for a $50 million manufacturing unit in the US, Enzene demonstrates a strategic focus on entering and strengthening its presence in the highly competitive US biotech market, opening avenues for US-based suppliers and partners.

Award-Winning Credibility Enzene's recognition with the 2025 CPHI Pharma Award for Manufacturing Excellence underscores its leadership in manufacturing innovation, making it an attractive partner for organizations valuing proven, award-winning biologics production capabilities.

Affordable Biosimilars The launch of Perzea, India’s most affordable Pertuzumab biosimilar, highlights Enzene’s commitment to cost-effective biotherapeutics, creating opportunities to target cost-sensitive markets and collaborate with healthcare providers seeking affordable biosimilar options.

Strategic Collaborations Enzene’s recent partnership with Virtuosi to develop a skilled pharmaceutical workforce, coupled with collaborations with Hetero Healthcare, signals a readiness to form strategic alliances that can enhance manufacturing capacity and market reach, ideal for vendors and service providers supporting biotech and pharma ecosystems.